Ranjana Advani, MD

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma.